US FDA to decide fate of Roche's basal cell carcinoma drug by March
This article was originally published in Scrip
Executive Summary
The US FDA on 8 November granted priority review for Roche's new drug application for vismodegib, an experimental treatment for adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.